|
| VPZ (VAM) therapy | PPI (PAM) therapy | p value |
| No. of patients enrolled | 274 | 464 |
|
| Age (Years) | 58.2 ± 11.6 | 60.7 ± 11.1 | 0.0048 |
| Gender |
|
| 0.6351 |
| Male | 139 | 227 |
|
| Female | 135 | 237 |
|
| BMI (kg/m2) | 22.7 ± 3.4 | 22.5 ± 2.9 | 0.2901 |
| First-line treatment |
|
| <0.0001 |
| with VPZ (VAC) | 129 | 0 |
|
| with PPI (PAC) | 126 | 464 |
|
| unknown | 19 |
|
|
| Endoscopic findings |
|
| 0.0028 |
| No abnormality | 16 | 3 |
|
| Duodenal ulcer | 5 | 9 |
|
| Atrophic gastritis | 242 | 427 |
|
| Gastric ulcer | 10 | 25 |
|
| After ER for GC | 1 | 0 |
|
| Smoking (yes) | 38 | 65 | 0.9577 |
| Drinking (yes) | 143 | 213 | 0.0988 |
| Successful eradication | 219 | 388 |
|
| ITT analysis % (95% CI) | 79.9 (74.8 - 84.2) | 83.6 (78.0 - 86.7) | 0.2045 |
| PP analysis % (95% CI) | 92.4 (88.3 - 95.1) | 93.3 (90.4 - 95.3) | 0.6736 |
| Adverse events (%, 95% CI) | 14 (5.1%, 3.1 - 8.4) | 12 (2.6%, 1.5 - 4.5) | 0.0724 |